You know what pharmacovigilance is, right?

What post-market monitoring mechanisms are in place to ensure the ongoing safety and efficacy of medicinal products after marketing authorisation has been granted?
 
In France, pharmacovigilance procedures aim to monitor, evaluate, prevent and manage the risk of an adverse reaction resulting from the use of medicinal products (Article L5121-22 of the Public Health Code). Pharmacovigilance involves the reporting of suspected medicinal product-related adverse reactions, including in case of overdose, misuse, abuse and medication errors (Article R5121-150 of the Public Health Code).
 
 
 
You can read the further content of this article by visiting https://www.lexology.com/library/detail.aspx?g=e9ce6383-5760-4178-851a-7d078c1bdc66&utm_source=Lexology+Daily+Newsfeed&utm_medium=HTML+email+-+Body+-+General+section&utm_campaign=Lexology+subscriber+daily+feed&utm_content=Lexology+Daily+Newsfeed+2018-03-16&utm_term=